

Francesca Re graduated in Medical Biotechnology from the University of Milano-Bicocca (UNIMIB) in 2005 and in 2008 completed a PhD degree in Neuroscience at UNIMIB with research conducted at the Laboratory of Biochemistry, School of Medicine and Surgery (Monza) at UNIMIB. From 2009, she worked with Prof. Massimo Masserini, a world-leading laboratory in Neuro-Nanomedicine, for a 6-year post-doctoral period. Starting from 2015, she is creating her independent line of research at the UNIMIB. During her scientific career, F.R. has published 37 articles in top international peer-reviewed journals (including high IF journals, i.e. ACSNano, IF 12.9; Biomaterials, IF 8.5; NanoResearch, IF 7.1 and J. Cont. Rel., IF 7.6); her h-index is 16 and has 707 citations (Scopus). Throughout her career, F.R. has been mainly focused in understanding the mechanisms to cross the BBB by macromolecules and nanoparticles for the potential therapy of Alzheimer's disease. F.R. is the coordinator of a H2020 Project funded by EU Joint Programme (JPND) in 2015, where will be developed a novel in vitro model of Alzheimer's disease-like BBB and she has been a recipient of different projects both as PI of the UNIMIB Unit and coordinator. In 2013, she was awarded of "63rd Lindau Nobel Laureate Meeting – Chemistry". F.R. has knowledge in drug discovery as she is co-inventor in 2 families of international patents and is Chief Operating Officer (COO)/Head of R&D of AmypoPharma S.r.l. (spin-off of UNIMIB).